TP53 and acute myeloid leukemia: In order to rule out the possibility that DCAF15 degrades p53 directly, we constructed TP53-WT AML cells expressing a doxycycline (Dox)-inducible shRNA targeting DCAF15. Analysis of the p53 protein half-life revealed no difference between cells expressing or lacking DCAF15, indicating that DCAF15 is not involved in p53 degradation (Supplementary Fig. 3a).